Answers are grounded in this paper and cite their sources.
Viewpoint demonstrates limitations of median survival in oncology trials, highlighting the need for milestone survival metrics to capture long-term treatment benefits.
This Viewpoint argues for adding the “milestone” metric of cancer treatment outcomes to the conventional “median” improvement metric because the median misses important milestones of treatment success (eg, 1-, 2-, and 5-year survival) in the tail end of the survival curve.
No takes yet. Share an insight, caveat, or question.
Hellmann et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: